Summary: Obesity is one of the major civilization problems of the 21st century. It is characterized by a multifactorial etiology and a tendency to recur. It is associated with the occurrence of more than 200 complications, which include disorders of carbohydrate metabolism, lipid metabolism, cardiovascular disease or cancer. In addition, it causes a significant deterioration in patients' quality of life and a reduction in the length of life. Successful treatment of obesity requires a comprehensive approach, at the core of which is non-pharmacological treatment, i.e. diet therapy, regular physical activity and psychological support. However, experience shows that the use of non-pharmacological intervention alone is insufficient and does not ensure long-term success. Therefore, an important pillar of obesity disease treatment is pharmacotherapy. Its rapid development in recent years enables us to fight obesity more and more effectively. However, despite the fact that registered drugs make it possible to reduce even more than 20% of body weight, this effect is sometimes insufficient. In addition, the etiology of the development of obesity is multifactorial, so the use of drugs with different mechanisms of action and point of action can produce a synergistic effect. To date, recommendations, both Polish and European, do not recommend such a procedure, but it is nevertheless not contraindicated. The number of available publications on the subject is limited, as we present in this article. However, given the complex nature of this disease - its multifactorial etiology, the difficulty of maintaining remission, and the occurrence of more than one of its phenotypes in almost 30% of patients, individualization of therapy is advisable, and the use of more than one OMM drug may be warranted.